{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:56:51Z","timestamp":1755601011848,"version":"3.40.4"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"Importance<\/jats:title>The uncertainties about the real-world effectiveness of adalimumab biosimilars limit their widespread adoption for psoriasis.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare the effectiveness of adalimumab biosimilars Amjevita and Imraldi with Humira for psoriasis.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>An emulation of 2 targeted pragmatic clinical trials was conducted using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), a prospective pharmacovigilance registry tracking individuals receiving biologic and conventional systemic treatments for psoriasis in the UK and the Republic of Ireland. Data from patients with psoriasis using adalimumab registered to BADBIR were included. Data were collected from September 2007 to January 2023, and data were analyzed from January to September 2023<\/jats:p><\/jats:sec>Exposures<\/jats:title>The effectiveness of initiating Amjevita and Imraldi were compared with initiating Humira among adalimumab-naive patients, and the effectiveness of switching from Humira to either Amjevita or Imraldi were compared with continuing Humira among patients who had been using Humira consistently for more than 2 years.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The study outcomes were absolute Psoriasis Area and Severity Index (PASI) score of 2 or less and PASI score of 4 or less at 12 months after the index date. Inverse propensity treatment weighting was used to analyze receiving either biosimilars or Humira to account for confounding. Multiple imputations were used to account for missing PASI data at 12 months and inverse probability of censoring weighting to account for censorship due to deviation from the treatments under investigation. Logistic regression models were fitted to compare the outcomes between study cohorts.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 11\u202f400 included patients, 6924 (60.7%) were male, and the mean (SD) age was 45.3 (12.5) years. A total of 6133 patients were identified in the new user analysis (5416 starting Humira, 382 starting Amjevita, and 335 starting Imraldi) and 5267 patients in the switcher analysis (3808 continuing Humira, 847 switching to Amjevita, and 612 switching to Imraldi). Amjevita and Imraldi new users had no significantly different probability of achieving a PASI score of 2 or less (Amjevita: adjusted odds ratio [aOR], 0.98; 95% CI, 0.78-1.25; Imraldi: aOR, 0.83; 95% CI, 0.64-1.07) and a PASI score of 4 or less (Amjevita: aOR, 1.07; 95% CI, 0.84-1.37; Imraldi: aOR, 0.91; 95% CI, 0.69-1.20) compared with Humira new users. Patients who switched to Amjevita and Imraldi also had no statistically significant differences in achieving a PASI score of 2 or less (Amjevita: aOR, 1.19; 95% CI, 0.94-1.51; Imraldi: aOR, 0.92; 95% CI, 0.72-1.18) and a PASI score of 4 or less (Amjevita: aOR, 1.32; 95% CI, 0.96-1.84; Imraldi: aOR, 1.00; 95% CI, 0.70-1.41) compared with those who continued Humira.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this study, Amjevita and Imraldi were as effective as Humira for both new starters and patients switching to biosimilars from Humira.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.0055","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:02:42Z","timestamp":1741190562000},"page":"358","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of Adalimumab Biosimilars and Originator for Psoriasis"],"prefix":"10.1001","volume":"161","author":[{"given":"Duc Binh","family":"Phan","sequence":"first","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research, Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony P.","family":"Bewley","sequence":"additional","affiliation":[{"name":"Barts Health NHS Trust and Queen Mary University of London Medical School, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Laws","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Leeds, Leeds, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teena","family":"Mackenzie","sequence":"additional","affiliation":[{"name":"Royal Berkshire NHS Foundation Trust, Reading, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine H.","family":"Smith","sequence":"additional","affiliation":[{"name":"St Johns Institute of Dermatology, Guys & St Thomas NHS Foundation Trust, Kings College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher E. M.","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research, Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom"},{"name":"Department of Dermatology, King\u2019s College Hospital, King\u2019s College London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lunt","sequence":"additional","affiliation":[{"name":"Versus Arthritis Epidemiology Unit, Division of Musculoskeletal & Dermatological Sciences, The University of Manchester, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research, Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenas Z. N.","family":"Yiu","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust, National Institute for Health and Care Research, Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"key":"doi250002r1","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"doi250002r2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/bjd\/ljad107","article-title":"Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).","volume":"189","author":"Phan","year":"2023","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi250002r4","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.xphs.2021.02.003","article-title":"Overview of Humira\u00ae biosimilars: current European landscape and future implications.","volume":"110","author":"Coghlan","year":"2021","journal-title":"J Pharm Sci"},{"issue":"6","key":"doi250002r5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40265-017-0717-1","article-title":"The language of biosimilars: clarification, definitions, and regulatory aspects.","volume":"77","author":"Declerck","year":"2017","journal-title":"Drugs"},{"issue":"4","key":"doi250002r6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4103\/jpgm.JPGM_109_19","article-title":"Pharmacovigilance of biosimilars - why is it different from generics and innovator biologics?","volume":"65","author":"Oza","year":"2019","journal-title":"J Postgrad Med"},{"key":"doi250002r7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.625296","article-title":"Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure.","volume":"12","author":"Vogler","year":"2021","journal-title":"Front Pharmacol"},{"issue":"7","key":"doi250002r8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/jamadermatol.2023.1338","article-title":"Biosimilars for the treatment of psoriasis: a systematic review of clinical trials and observational studies.","volume":"159","author":"Phan","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi250002r9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034183","article-title":"Physicians\u2019 perceptions of the uptake of biosimilars: a systematic review.","volume":"10","author":"Sarnola","year":"2020","journal-title":"BMJ Open"},{"issue":"1","key":"doi250002r10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.18553\/jmcp.2019.25.1.102","article-title":"Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review.","volume":"25","author":"Leonard","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"doi250002r11","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"doi250002r12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses.","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"doi250002r13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1365-2133.2012.10835.x","article-title":"The British Association of Dermatologists\u2019 Biologic Interventions Register (BADBIR): design, methodology and objectives.","volume":"166","author":"Burden","year":"2012","journal-title":"Br J Dermatol"},{"key":"doi250002r14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s40471-024-00346-2","article-title":"The clone-censor-weight method in pharmacoepidemiologic research: foundations and methodological implementation.","volume":"11","author":"Gaber","year":"2024","journal-title":"Curr Epidemiol Rep"},{"issue":"11","key":"doi250002r15","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).","volume":"135","author":"Warren","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"10","key":"doi250002r16","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis.","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"7","key":"doi250002r17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-075197","article-title":"Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study.","volume":"13","author":"Phan","year":"2023","journal-title":"BMJ Open"},{"issue":"6","key":"doi250002r18","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1111\/bjd.15857","article-title":"Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.","volume":"177","author":"Papp","year":"2017","journal-title":"Br J Dermatol"},{"issue":"11","key":"doi250002r19","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2340\/00015555-3245","article-title":"Absolute and relative Psoriasis Area and Severity Indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis: an integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes.","volume":"99","author":"Puig","year":"2019","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"doi250002r20","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).","volume":"182","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi250002r21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12874-017-0442-1","article-title":"When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts.","volume":"17","author":"Jakobsen","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"doi250002r22","doi-asserted-by":"publisher","first-page":"b2393","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls.","volume":"338","author":"Sterne","year":"2009","journal-title":"BMJ"},{"issue":"3","key":"doi250002r23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1177\/0962280210395740","article-title":"Review of inverse probability weighting for dealing with missing data.","volume":"22","author":"Seaman","year":"2013","journal-title":"Stat Methods Med Res"},{"key":"doi250002r3","unstructured":"National Health Service. Commissioning intentions: adalimumab. Accessed January 30, 2024. https:\/\/www.sps.nhs.uk\/wp-content\/uploads\/2018\/09\/20180925-Contractual-Commissioning-Intentions-Adalimumab_corporate-template.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2830692\/jamadermatology_phan_2025_oi_250002_1744811591.39185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T15:00:45Z","timestamp":1744815645000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2830692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.0055","relation":{},"ISSN":["2168-6068"],"issn-type":[{"type":"print","value":"2168-6068"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}